Larvol Delta - Aprea-Therapeutics-Presents-Updated-Phase-1-Data-on-WEE1-Inhibitor-APR1051-at-ASCO-2026-Demonstrating-Early-Monotherapy-Activity-and-Manageable-Tolerability-in-Advanced-Solid-Tumors

APR-1051 - Aprea

https://www.globenewswire.com/news-release/2026/06/01/3304318/0/en/Aprea-Therapeutics-Presents-Updated-Phase-1-Data-on-WEE1-Inhibitor-APR-1051-at-ASCO-2026-Demonstrating-Early-Monotherapy-Activity-and-Manageable-Tolerability-in-Advanced-Solid-Tumo.html

Jun 1, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next